Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

1.480 +0.240 (+19.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
Dow Down Triple Digits as Fed Meeting Wraps Up
Stocks have deepened their morning losses by midday, with the Dow Jones Industrial Average down 119 points, while both the Nasdaq Composite and S&P 500 Index are firmly in the red as well. 
Via Talk Markets
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates
Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S... 
Via Benzinga
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
Photo by Raimond Klavins 
Via Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics... 
Via Benzinga
Topics Death
Exposures Death
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
Photo by Michael Longmire on... 
Via Benzinga
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
Via Investor Brand Network
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent invest... 
Via Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Analyst Ratings For ATAI Life Sciences
Over the past 3 months, 6 analysts have published their opinion on ATAI Life Sciences (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ... 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Analyst Ratings For ATAI Life Sciences
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021
Upgrades Barrington Research upgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE: 
Via Benzinga
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,... 
Via FinancialNewsMedia
Topics Law Enforcement
Exposures COVID-19 Legal
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug... 
Via Benzinga
ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study
ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated... 
Via Benzinga
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.